10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
Open accessAbstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Biomarkers such as elevated blood pressure, lipid levels, and inflammatory markers are closely associated with CVD risk, and treatments that reduce these markers can reduce CVD risk in populations with and without diabetes.
“Biomarkers such as elevated blood pressure, lipid levels, and inflammatory markers are closely associated with CVD risk, and treatments that reduce these markers can reduce CVD risk in populations with and without diabetes [11–13].”
In the DAPA-HF trial, dapagliflozin treatment had a lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59-0.83]) compared with placebo.
“lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59-0.83]),”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [307]
In the DAPA-HF trial, dapagliflozin treatment had a lower risk of the primary outcome of worsening heart failure or cardiovascular death (HR 0.74 [95% CI 0.65-0.85]) compared with placebo.
“Dapagliflozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65-0.85]),”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [307]
Statin prescriptions also appeared among important predictors, consistent with their indication for patients with diabetes and cardiovascular risk factors whose greater clinical complexity increases the likelihood of experiencing acute events requiring emergency care.
“Statin prescriptions also appeared among important predictors, consistent with their indication for patients with diabetes and cardiovascular risk factors whose greater clinical complexity [86,87] increases the likelihood of experiencing acute events requiring emergency care [88–90].”
From Machine learning-driven risk prediction for post-hospitalization diabetes case management: Integrating clinical and social determinants of health (2026) · cites this paper as [88]
The citation lists haven’t been fetched yet
References 331 · Cited by 438
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Kosiborod, M. N., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Das, Sandeep R.
- Ekhlaspour, Laya
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Kosiborod, Mikhail N.
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S179-S218
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725811
- OpenAlex
- W4389560873
- Cited by
- 438
- References
- 331
- Citations by year
- 2026: 93 · 2025: 193 · 2024: 152
- FWCI
- 15.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, diabetes mellitus, cardiovascular risk management, clinical guidelines, quality of care, treatment goals
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
